ESMO Open最新文献

{"title":"Phase II trial, multicenter, first-line paclitaxel-avelumab treatment of inoperable angiosarcoma (KCSG UN 18-15)☆","authors":"H.R. Kim ,&nbsp;M. Kim ,&nbsp;M.J. Kang ,&nbsp;J.E. Kim ,&nbsp;Y.J. Kim ,&nbsp;K. Park ,&nbsp;W.K. Bae ,&nbsp;M.-W. Lee ,&nbsp;J.-Y. Hong ,&nbsp;Y.S. Kim ,&nbsp;S.-A. Im ,&nbsp;J. Lee ,&nbsp;S.Y. Oh","doi":"10.1016/j.esmoop.2025.106018","DOIUrl":"10.1016/j.esmoop.2025.106018","url":null,"abstract":"<div><h3>Background</h3><div>Angiosarcomas are rare tumors of vascular or lymphatic origin with clinically heterogeneous presentation and behavior, predominantly originating in the skin of the head and neck and the breast area. Given their location and/or rapid progression, surgical resection is frequently not feasible, even in those with localized diseases. Conventional cytotoxic chemotherapy has proven largely ineffective against angiosarcoma. In this prospective, phase II study, we evaluated the efficacy and toxicity of paclitaxel plus avelumab as first-line therapy for unresectable angiosarcoma.</div></div><div><h3>Patients and methods</h3><div>This study included patients with unresectable locally advanced or metastatic angiosarcomas, who did not receive systemic treatment. Paclitaxel (80 mg/m²) was intravenously infused on days 1, 8, and 15 of every 28-days cycle; avelumab (10 mg/kg) was intravenously infused every 2 weeks. Treatment continued until disease progression, unacceptable toxicity, death, or withdrawal of consent, whichever occurred first. The primary endpoint was the objective response rate (ORR); secondary endpoints included overall survival (OS), progression-free survival (PFS), and safety profiles.</div></div><div><h3>Results</h3><div>The final analysis included 32 patients (21 male and 11 female). The median age was 63.5 years (range 27-82 years). The ORR was 50.0% (<em>n</em> = 16), including one complete response. Median OS and PFS were 14.5 [95% confidence interval (CI) 9.4-24.6 months] and 6.0 (95% CI 5.4-9.5 months), respectively. Among patients who received at least one treatment dose (<em>n</em> = 33), adverse events (AEs) of any grade were reported in 90.9% (<em>n</em> = 30), and severe AEs in 12.1% (<em>n</em> = 4), including one death. The most common hematologic and non-hematologic AEs were neutropenia (<em>n</em> = 13, 39.4%) and pain (<em>n</em> = 12, 36.4%). Immune-related pneumonitis was reported in two patients.</div></div><div><h3>Conclusion</h3><div>Avelumab plus weekly paclitaxel demonstrated preliminary evidence of efficacy and tolerability in inoperable angiosarcoma. Given the rarity of angiosarcoma, further multicenter, collaborative, and translational studies are warranted.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 2","pages":"Article 106018"},"PeriodicalIF":8.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146024928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence-powered real-time multimodal model for predicting recurrence and survival in head and neck cancer: a multicenter, multinational study","authors":"H.A. Jung ,&nbsp;R. Merkin ,&nbsp;A.L. Feng ,&nbsp;D. Lee ,&nbsp;K. Lee ,&nbsp;S. Park ,&nbsp;J.-M. Sun ,&nbsp;S.-H. Lee ,&nbsp;J.S. Ahn ,&nbsp;M.-J. Ahn ,&nbsp;L.J. Wirth ,&nbsp;J.C. Park","doi":"10.1016/j.esmoop.2025.106046","DOIUrl":"10.1016/j.esmoop.2025.106046","url":null,"abstract":"<div><h3>Background</h3><div>Head and neck squamous-cell carcinoma (HNSCC) accounts for ∼5.3% of cancer-related mortality worldwide, with an estimated 890 000 new diagnoses and 450 000 deaths annually. Despite curative-intent therapy, 10% to 50% of patients experience recurrence. Prognosis for recurrent or metastatic disease is poor, with limited treatment options, underscoring the need for accurate prognostic models to guide treatment escalation or de-escalation and avoid over-treatment.</div></div><div><h3>Methods</h3><div>We conducted a multicenter prognostic study of patients undergoing curative-intent surgery at Samsung Medical Center and Massachusetts Eye and Ear Infirmary/Massachusetts General Hospital from 2008 to 2024. Baseline clinicopathologic variables were integrated with longitudinal laboratory measurements from surveillance. A random 80/20 split defined development and internal-validation cohorts. Using XGBoost, we trained two models to predict recurrence-free survival (RFS) and overall survival (OS) at 1, 2, 3, 4, and 5 years from each visit.</div></div><div><h3>Results</h3><div>A total of 975 patients with HNSCC (oral cavity, oropharyngeal, hypopharyngeal, and laryngeal subsites) were included. The areas under the curve (AUCs) for predicting 1-, 2-, 3-, 4-, and 5-year RFS from the surveillance time point were 0.785 (sensitivity, 72.8%; specificity, 71.5%), 0.831 (79.7%; 73.7%), 0.788 (74.0%; 73.3%), 0.769 (72.6%; 70.5%), and 0.795 (72.1%; 74.7%), respectively. For OS prediction, AUCs were 0.788 (72.1%; 73.6%), 0.797 (75.7%; 71.8%), 0.796 (81.0%; 68.4%), 0.820 (77.5%; 76.5%), and 0.815 (75.8%; 75.8%), respectively. In subgroup analysis, the model showed strong OS prediction in human papilloma virus (HPV)-positive oropharyngeal cancer, with AUCs of 0.943, 0.736, 0.699, 0.835, and 0.765 at 1-, 2-, 3-, 4-, and 5-years, respectively. In non-HPV-positive HNSCC, OS AUCs ranged from 0.780 to 0.813 and RFS AUCs from 0.774 to 0.830 across the same time points.</div></div><div><h3>Conclusions and relevance</h3><div>In this multicenter study, an artificial intelligence (AI)-powered model using multimodal and longitudinal data accurately predicted RFS and OS at multiple time points following curative-intent surgery for HNSCC.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 2","pages":"Article 106046"},"PeriodicalIF":8.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146075212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mutational patterns and ancestry-linked profiles in a large hepatocellular carcinoma and combined hepatocellular–cholangiocarcinoma cohort☆","authors":"C. Gerdes ,&nbsp;S. Rengarajan ,&nbsp;K. Murugesan ,&nbsp;J.S. Ross ,&nbsp;S. Bartels ,&nbsp;A. Vogel ,&nbsp;A. Saborowski","doi":"10.1016/j.esmoop.2025.106048","DOIUrl":"10.1016/j.esmoop.2025.106048","url":null,"abstract":"<div><h3>Background</h3><div>Despite significant therapeutic advancements, hepatocellular carcinoma (HCC) remains a highly fatal malignancy. To accelerate the development of targeted therapies, a comprehensive understanding of the spectrum of genomic alterations (GAs) is essential. Here, we present what is, to our knowledge, the largest genomic analysis of real-world HCC and combined HCC–cholangiocarcinoma (cHCC–CCA) patients.</div></div><div><h3>Patients and methods</h3><div>Tumor samples from 2372 HCC patients and 150 patients with cHCC–CCA underwent genomic profiling using the FoundationOne® platform covering &gt;290 genes, as well as tumor mutational burden (TMB) and microsatellite status.</div></div><div><h3>Results</h3><div>Our comprehensive and representative analysis included 1793 male and 577 female patients across five genetic ancestries. Female patients exhibited lower frequencies of GAs in <em>TERT</em>, <em>MYC</em>, and <em>CTNNB1,</em> with higher rates of <em>BAP1</em> GA. Patients of East Asian ancestry presented an increased frequency of <em>TP53</em>, <em>MUTYH</em>, and <em>TET2</em> GAs, as well as a higher proportion of TMB-high tumors. Compared with HCC, cHCC–CCA exhibited higher frequencies of <em>IDH1</em> (8.0% versus 0.3%), <em>IDH2</em> (2.7% versus 0.04%), and <em>FGFR2</em> (7.3% versus 0.3%) alterations. Potentially actionable alterations were detected in 19.5% of HCC patients and 34.7% of mixed histology. Histological re-assessment due to detection of GA uncommon for HCC was carried out in 117 patients, resulting in a change in diagnosis in 37 cases. Limitations include the absence of detailed clinical data and dependence on the CE-certified Foundation Medicine (FMI) platform for functional annotation of detected variants.</div></div><div><h3>Conclusions</h3><div>Our study represents one of the largest cohorts of HCC and cHCC–CCA patients with genomic data and highlights the critical role of integrated molecular diagnostics. Beyond uncovering therapeutic targets, next-generation sequencing profiling offers significant benefits in improving diagnostic accuracy for liver cancer.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 2","pages":"Article 106048"},"PeriodicalIF":8.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146017759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of ECOG performance status 2 participants on outcomes of pivotal cancer clinical trials: a meta-analysis and meta-regression","authors":"G.M. Iannantuono ,&nbsp;T. Giovagnoli ,&nbsp;L. Mastrantoni ,&nbsp;B. Gyawali ,&nbsp;C.S. Floudas ,&nbsp;S. Sganga ,&nbsp;D. Giannarelli ,&nbsp;M. Filetti ,&nbsp;A. Spinazzola ,&nbsp;F. Lo Bianco ,&nbsp;E. Giudice ,&nbsp;A. Vitale ,&nbsp;J.L. Gulley ,&nbsp;P. Navarra ,&nbsp;E. Bria ,&nbsp;G. Daniele","doi":"10.1016/j.esmoop.2026.106065","DOIUrl":"10.1016/j.esmoop.2026.106065","url":null,"abstract":"<div><h3>Background</h3><div>Although patients with Eastern Cooperative Oncology Group performance status (PS) of 2 constitute a significant proportion of the cancer population, they are often excluded from pivotal clinical trials owing to presumed higher risks of treatment effect dilution, toxicity, and lower compliance. Here, we conducted a systematic review and meta-analysis to evaluate the impact of including PS 2 participants on efficacy and safety outcomes in pivotal cancer clinical trials.</div></div><div><h3>Materials and methods</h3><div>We searched the ‘Oncology/Hematologic Malignancies Approval Notifications’ and ‘Drugs@FDA' databases for clinical trials supporting ‘Food and Drug Administration' anticancer drug approvals from 1 January 2009 to 31 December 2024. Eligible studies were randomized phase III clinical trials of systemic therapies for metastatic solid tumors permitting the inclusion of PS 2 participants. We assessed efficacy outcomes [progression-free survival (PFS) and overall survival (OS)] and safety outcomes [occurrence of any-grade adverse events (AEs), high-grade AEs, serious AE (SAEs), AE-related deaths, and treatment modifications] in the included studies.</div></div><div><h3>Results</h3><div>Thirty-six trials were included. In subgroup analyses, no statistically significant differences were found between PS 2 and PS ≤1 participants for PFS [hazard ratio (HR) 0.45, 95% confidence interval (CI) 0.30-0.69 versus HR 0.52, 95% CI 0.41-0.66, <em>P</em> = 0.59] and OS (HR 0.81, 95% CI 0.68-0.97 versus HR 0.71, 95% CI 0.66-0.77, <em>P</em> = 0.18). In meta-regression analyses, no significant associations were found for efficacy outcomes. However, a higher proportion of PS 2 participants was significantly associated with an increased risk of SAEs, AE-related deaths, and treatment discontinuations.</div></div><div><h3>Conclusions</h3><div>Although PS 2 participants showed a greater propensity to serious toxicity, no significant differences in efficacy outcomes were observed compared with those with PS ≤1. Our results support the inclusion of PS 2 participants in clinical trials, as their exclusion limits the generalizability of results.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 2","pages":"Article 106065"},"PeriodicalIF":8.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146112590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic nomogram for patients with HER2-negative metastatic gastric cancer receiving first-line PD-1 blockade","authors":"B. Fu ,&nbsp;M. Zhang ,&nbsp;T. Fang ,&nbsp;Y. Wang ,&nbsp;Y. Jin ,&nbsp;Y. Wang ,&nbsp;Z. Wang ,&nbsp;Y. Li ,&nbsp;F. Wang ,&nbsp;H. Luo ,&nbsp;M. Qiu ,&nbsp;J. Li ,&nbsp;F. Wang ,&nbsp;D. Zhang","doi":"10.1016/j.esmoop.2025.106055","DOIUrl":"10.1016/j.esmoop.2025.106055","url":null,"abstract":"<div><h3>Background</h3><div>Programmed cell death protein 1 (PD-1) blockade-based therapies have become the new standard for first-line treatment of metastatic gastric cancer (mGC), but a lack of effective prognostic models hinders precise risk stratification in patients receiving this treatment. We aimed to develop an intuitive prognostic nomogram for human epidermal growth factor receptor 2 (HER2)-negative mGC patients receiving first-line anti-PD-1 therapies.</div></div><div><h3>Patients and methods</h3><div>We conducted a retrospective study and collected baseline clinicopathological characteristics of patients with HER2-negative mGC receiving first-line PD-1 blockade-based therapies from October 2018 to July 2024. Cox regression models were utilized to determine independent prognostic factors. Time-dependent receiver operating characteristic (ROC) curves with area under the curves (AUCs), calibration plots and decision curve analyses (DCAs) were used to validate the nomogram.</div></div><div><h3>Results</h3><div>A total of 714 patients were included in the training cohort and 180 in the validation cohort. After univariate and multivariate Cox regression analyses, Eastern Cooperative Oncology Group performance status, pleural or peritoneal metastases, Lauren type, C-reactive protein and elevated lactate dehydrogenase were identified as independent prognostic factors associated with both progression-free survival (PFS) and overall survival (OS), and were used to develop a prognostic nomogram based on OS in the training cohort. The nomogram showed reasonable discrimination and good calibration in both the training and validation cohorts. Time-dependent ROC and DCAs indicated superior performance of the nomogram to programmed death-ligand 1 combined positive score and several previously reported models. Three risk groups were stratified according to the nomogram scores. Whether in the training or the validation cohort, patients in the intermediate- and high-risk groups had significantly inferior PFS and OS compared with those in the low-risk group (all <em>P</em> &lt; 0.001). The risk stratification was significantly associated with disease control rates. Nevertheless, external validation is needed in the future for the generalizability of the nomogram.</div></div><div><h3>Conclusions</h3><div>The nomogram provided personalized survival prediction for patients with HER2-negative mGC receiving first-line PD-1 blockade-based therapies and enabled prognostic stratification to identify patients with different survival risks.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 2","pages":"Article 106055"},"PeriodicalIF":8.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146131536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paclitaxel plus cetuximab for the treatment of R/M SCCHN after first-line pembrolizumab failure: primary analysis from the PaceAce trial","authors":"T. Fuereder ,&nbsp;K. Klinghammer ,&nbsp;D. Hahn ,&nbsp;B. Grünberger ,&nbsp;T. Melchardt ,&nbsp;R. Greil ,&nbsp;F. Kocher ,&nbsp;G. Gamerith ,&nbsp;C. Wagner ,&nbsp;L. Berchtold ,&nbsp;M. Burian ,&nbsp;A. Strobl","doi":"10.1016/j.esmoop.2026.106061","DOIUrl":"10.1016/j.esmoop.2026.106061","url":null,"abstract":"<div><h3>Background</h3><div>No standard second-line treatment has been established for patients with recurrent or metastatic (R/M) squamous-cell carcinoma of the head and neck (SCCHN) progressing after first-line pembrolizumab-based therapy, representing a critical evidence gap in current clinical practice.</div></div><div><h3>Patients and methods</h3><div>Patients with R/M SCCHN of the oropharynx, hypopharynx, larynx, or oral cavity, progressing after first-line pembrolizumab-based regimens, received paclitaxel (PTX) 175 mg/m² every 21 days plus weekly cetuximab (C) 250 mg/m² for up to six cycles, followed by C maintenance. The primary endpoint was overall response rate (ORR) at 12 weeks. Secondary endpoints included best overall response (BoR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), duration of response (DoR), quality of life, and safety.</div></div><div><h3>Results</h3><div>Fifty-seven patients were enrolled (median age 64 years). Twenty-five patients (43.9%) had a primary tumor in the oropharynx, 17 (29.8%) in the oral cavity, 9 (15.8%) in the hypopharynx, and 6 (10.5%) in the larynx. The ORR was 43.9% [95% confidence interval (CI) 30.7% to 57.6%], the BoR was 47.4% (95% CI 34.0% to 61.0%) with nine (15.8%) complete responses, and the DCR was 71.9% (95% CI 58.5% to 83.0%). DoR was 5.7 months (95% CI 5.1 months-not reached). Median PFS and OS were 5.9 months (95% CI 5.5-8.4 months) and 12.2 months (95% CI 10.5-17.6 months), respectively. Six-month PFS and OS rates were 49.0% and 73.0%, respectively. The most frequent non-hematological treatment-related adverse events were C-associated skin rash (78.9%) and PTX-related polyneuropathy (35.1%).</div></div><div><h3>Conclusions</h3><div>This is the first prospective trial specifically evaluating PTX plus C after failure of first-line pembrolizumab-based therapy in patients with R/M SCCHN. The observed clinical activity and tolerability support this widely available regimen as a potential standard-of-care option in the absence of randomized evidence in this setting.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 2","pages":"Article 106061"},"PeriodicalIF":8.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146131563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PP212 Systematic pan-cancer analysis identified NCOA4 as an immunological and prognostic biomarker and validated in lung adenocarcinoma","authors":"An Wang ,&nbsp;Yne-Ye Mao ,&nbsp;Tao Li ,&nbsp;Xin Zhou ,&nbsp;Yi-Bing Bai ,&nbsp;Tong Zhang ,&nbsp;Zhi-Qiang Ma ,&nbsp;Yi Hu","doi":"10.1016/j.esmoop.2025.105988","DOIUrl":"10.1016/j.esmoop.2025.105988","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 105988"},"PeriodicalIF":8.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147426550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PP134 Predicting micrometastatic recurrence after colorectal cancer surgery using patient-specific circulating tumor DNA surveillance and mathematical modeling","authors":"Rifaldy Fajar ,&nbsp;Prihantini Prihantini ,&nbsp;Rini Winarti ,&nbsp;Sahnaz Vivinda Putri ,&nbsp;Pia Elsa Makora ,&nbsp;Elfiany Syafruddin","doi":"10.1016/j.esmoop.2025.105977","DOIUrl":"10.1016/j.esmoop.2025.105977","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 105977"},"PeriodicalIF":8.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147426553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PP124 An alternative approach to combat colorectal cancer metastasis by neutrophil extracellular traps (NETs) using galangal-based synthetic compound (PK3)","authors":"Podchanart Wanitchakool ,&nbsp;Mashima Naksawat ,&nbsp;Lalida Sirianan ,&nbsp;Pakit Kambunma","doi":"10.1016/j.esmoop.2025.105972","DOIUrl":"10.1016/j.esmoop.2025.105972","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 105972"},"PeriodicalIF":8.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147412603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PP190 Real-world evaluation of patient characteristics, and treatment patterns in locally advanced or metastatic urothelial cancer following approval of maintenance therapy in South Korea","authors":"Li-Jen Cheng ,&nbsp;Eo Jin Kim ,&nbsp;Kyungah Park ,&nbsp;David Nimke ,&nbsp;Eunjee Cho ,&nbsp;Mia Unsworth ,&nbsp;Maria Walley ,&nbsp;Amber Simpson","doi":"10.1016/j.esmoop.2025.105985","DOIUrl":"10.1016/j.esmoop.2025.105985","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 105985"},"PeriodicalIF":8.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147413564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}